Repros Therapeutics (RPRX) Announces FDA Meeting to Discuss Phase 3 Efficacy Studies of Androxal
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics Inc. (Nasdaq: RPRX) announced that the FDA has granted a meeting with the Company to discuss the design of pivotal Phase 3 efficacy studies for Androxal, as well as the components of the overall drug development program required for NDA submission. The meeting has been scheduled for the first half of May, 2012.
Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Androxal treats the underlying mechanism that the Company believes results in the majority of the cases of secondary hypogonadism.
Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Androxal treats the underlying mechanism that the Company believes results in the majority of the cases of secondary hypogonadism.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA extends Capricor's deramiocel review deadline to November 2026
- FDA confirms BioCardia meeting minutes on Helix catheter De Novo pathway
- American EcoFuels plans up to 584 new patent filings for fuel tech
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
